Glutamatergic medication in the treatment of Obsessive Compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD)

Glutamatergic medication in the treatment of Obsessive Compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD) - GOAT studies in TACTICS

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41943

Enrollment

Registered

2015-12-21

Start date

2017-01-11

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessief Compulsieve Stoornis Autism Spectrum Disorder and Obsessive Compulsive Disorder

Interventions

This study involves a comparison of an active drug (memantine) with matching placebo. During Study Period II, medication will be initiated and modified according to the weight group of the patient a

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: ASD and OCD inpatients or outpatients Age 6 (ASD) or 8 (OCD) untill 17;9 years at initial inclusion CGI-S score >/

Exclusion criteria

Exclusion criteria: Body weight

Design outcomes

Primary

Measure	Time frame
Primary endpoints are measures of * Baseline-to-endpoint change in symptoms/scale scores of compulsivity (CY-BOCS Total score), * adverse event rates and profile (spontaneous reporting, structured (short) AE scale, laboratory measures).	—

Secondary

Measure	Time frame
Genotypes of single common and rare variants in candidate genes, and also combined genetic variants in whole genes or neurotransmitter systems / gene pathways; Further lab assessments of various proteins in blood plasma.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)